Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13291
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHu, X Fen
dc.contributor.authorVeroni, Men
dc.contributor.authorDe Luise, Men
dc.contributor.authorWakeling, Aen
dc.contributor.authorSutherland, Ren
dc.contributor.authorWatts, C Ken
dc.contributor.authorZalcberg, John Ren
dc.date.accessioned2015-05-16T03:06:59Z
dc.date.available2015-05-16T03:06:59Z
dc.date.issued1993-11-11en
dc.identifier.citationInternational Journal of Cancer. Journal International Du Cancer; 55(5): 873-6en
dc.identifier.govdoc8244585en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/13291en
dc.description.abstractBoth primary and acquired resistance to the growth-inhibitory effects of anti-estrogens (e.g., tamoxifen) limits the clinical usefulness of these drugs in the treatment of breast cancer. The new, steroidal anti-estrogen ICI 182,780 was tested for its ability to inhibit the proliferation of a tamoxifen-resistant variant of the parental MCF-7 human breast-cancer cell line. Two cell lines cloned from the MCF-7 line were used for these experiments: a tamoxifen-sensitive line, MCF 5-21, and a tamoxifen-resistant line, MCF 5-23. Compared with tamoxifen, ICI 182,780 appeared to be 150 and 1540 times more effective in inhibiting cell growth in the 5-21 and 5-23 sub-lines respectively. ICI 182,780 completely circumvented tamoxifen resistance at a concentration of (5 to 10) x 10(-9) M in this model. Based on IC50 concentrations, the 5-23 line was 22-fold more resistant to tamoxifen than the 5-21 line, but only 2-fold more resistant to ICI 182,780, reducing relative resistance by 10-fold in the resistant line. There were no differences in ER parameters between the 2 lines. ER numbers/cell were: 40500 and 34800 and the KD 0.48 and 0.15 x 10(-9) M in the 5-21 and 5-23 cells respectively. In the 5-23 cells, the concentrations of ICI 182,780 and tamoxifen resulting in a 50% inhibition of 3H-estradiol binding were 2.3 x 10(-8) M and 1 x 10(-6) M, respectively (cf. estradiol 0.89 x 10(-9) M). Thus, one potential mechanism for the increased effectiveness of ICI 182,780 may relate to the increased affinity of this drug for the estrogen receptor as compared with tamoxifen.en
dc.language.isoenen
dc.subject.otherBinding Sitesen
dc.subject.otherBreast Neoplasms.pathologyen
dc.subject.otherCell Division.drug effectsen
dc.subject.otherDrug Resistanceen
dc.subject.otherEstradiol.analogs & derivatives.metabolism.pharmacologyen
dc.subject.otherHumansen
dc.subject.otherReceptors, Estrogen.metabolismen
dc.subject.otherTamoxifen.pharmacologyen
dc.subject.otherTumor Cells, Cultureden
dc.titleCircumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780.en
dc.typeJournal Articleen
dc.identifier.journaltitleInternational journal of cancer. Journal international du canceren
dc.identifier.affiliationDepartment of Medicine, Heidelberg Repatriation Hospital, Victoria, Australiaen
dc.description.pages873-6en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/8244585en
dc.type.austinJournal Articleen
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Feb 6, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.